Could Chemomab and Scipher Medicine turn an old RA market into a precision medicine story?
Chemomab Therapeutics Ltd. and Scipher Medicine Corporation have entered into an all-stock merger agreement to create a Nasdaq-listed precision immunology company focused initially on nebokitug, a first-in-class anti-CCL24 antibody planned for a Phase 2 rheumatoid arthritis trial. The combined company is expected to operate as Scipher Medicine Corporation and trade under the ticker symbol SCIP,